Spinal Restoration, Baxter in fibrin sealant partnership:
This article was originally published in Clinica
Minimally-invasive back pain therapy specialist Spinal Restoration has entered into an exclusive long-term agreement with Baxter Healthcare to develop and further expand the applications of the former's Biostat Biologx fibrin sealant. The deal will see Biostat Biologx combined with Baxter's own fibrin sealant to create the Biostat disc augmentation system, a minimally-invasive product for the treatment of painful degeneration of intervertebral discs. Spinal Restoration (Austin, Texas) said that the partnership will enable it to further its preparation for an investigational device exemption clinical study, scheduled for the first quarter of 2008.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.